George Sands, Nisha Bansal and Wolfgang C. Winkelmayer/LinkedIn
Jun 5, 2026, 18:32
George Sands: A Thoughtful Editorial on Low-Dose Rivaroxaban in Advanced CKD
George Sands, Ex-Senior Medical Director of Pfizer, Principal of Sands Collaborative, shared a post on LinkedIn about a recent article by Nisha Bansal and Wolfgang C. Winkelmayer, published in JAMA, adding:
“Sharing a very thoughtful editorial by Bansal and Winkelmyer about a trial in CKD patients, stage 4 and 5.
This randomized study is very helpful. This patient population is very challenging to randomize in clinical trials.
This was a placebo-controlled trial vs low-dose rivaroxaban.
The editorial sums it all up beautifully; approximately 5-minute read.”
Title: Rivaroxaban for Cardiovascular Disease Prevention in Chronic Kidney Disease
Authors: Nisha Bansal, Wolfgang C. Winkelmayer
Stay updated on all sceintific advances with Hemostasis Today.
-
Jul 26, 2026, 01:48Rob Maloney: Why Global Diagnosis is the Missing Piece in Bleeding Disorder Care
-
Jul 26, 2026, 01:35Moustafa Abdou: Ehlers-Danlos Syndrome – Why Collagen Matters for Hemostasis
-
Jul 26, 2026, 01:25Vrisha Shah: Exploring Transgenic Mouse Models for Pregnancy Outcomes at ISTH 2026
-
Jul 26, 2026, 01:06Christine Bork: Why Misinformation Around a Single Vitamin Postpartum is Putting Babies at Risk
-
Jul 26, 2026, 00:44A Significant Step Forward For People With Bleeding Disorders In The Dominican Republic – WFH
-
Jul 25, 2026, 18:00The Evolving Landscape of Factor Replacement Therapy – EAHAD
-
Jul 25, 2026, 17:43Heghine Khachatryan: Advancing Care for Women and Girls With Hemophilia
-
Jul 25, 2026, 17:00Revathy R Menon: A Memorable Milestone at the 39th ISBT Congress
-
Jul 25, 2026, 16:19Nicola Potere: From Scientific Exchange to Global Collaboration at ISTH 2026